ΓΙΑΚΔΡΚΙΓΙΚΗ ΠΡΟΠΔΛΑΗ ΚΑΙ ΑΓΓΔΙΟΠΛΑΣΙΚΗ: ΤΜΒΟΤΛΔ ΚΑΙ ΜΤΣΙΚΑ

Size: px
Start display at page:

Download "ΓΙΑΚΔΡΚΙΓΙΚΗ ΠΡΟΠΔΛΑΗ ΚΑΙ ΑΓΓΔΙΟΠΛΑΣΙΚΗ: ΤΜΒΟΤΛΔ ΚΑΙ ΜΤΣΙΚΑ"

Transcription

1 ΓΙΑΚΔΡΚΙΓΙΚΗ ΠΡΟΠΔΛΑΗ ΚΑΙ ΑΓΓΔΙΟΠΛΑΣΙΚΗ: ΤΜΒΟΤΛΔ ΚΑΙ ΜΤΣΙΚΑ ΓΙΔΝΔΡΓΔΙΑ ΠΡΩΣΟΓΔΝΟΤ ΓΙΑΓΔΡΜΙΚΗ ΣΔΦΑΝΙΑΙΑ ΠΑΡΔΜΒΑΗ ΑΠΟ ΣΗΝ ΚΔΡΚΙΓΙΚΗ ΑΡΣΗΡΙΑ Λάμπρος Κ. Μόσιαλος Γιεσθσντής Δπεμβατικός Καρδιολόγος ΓΝΘ «Παπαγεωργίοσ»

2 Patient characteristics 53 yo M presented to the ED with chest pain lasting 30 min. Heavy smoker ECG showed ST-e in II III avf V6 Given ASA, Prasugrel Radial access chosen

3 DIAGNOSTIC CorAngio Direct PPCI in RCA - TRA

4

5

6

7

8

9 DIAGNOSTIC CorAngio Direct PPCI in LAD - TRA

10 Patient characteristics 67 yo M with chest discomfort lasting 12 h NIDDM, Smoker ST-e in II III avf predominantly in III, ST-d in I avl V5 V6 Given ASA, Prasugrel Radial access.

11

12

13

14

15

16

17 Direct PPCI probable contribution Shortening of D2B time Prevention of artery spasm Reduced contrast administration Less fluoroscopy time More cost effective

18 TRA-PPCI in PAPAGEORGIOU CATH LAB Overall cases 1585 Diagnostic 684 PCI. 553 TRA (81%) 109 Primary PCIs 81 TRA (74%)

19 KATANOMH PPCI ΜΔ ΒΑΗ ΣΗΝ ΟΓΟ ΠΡΟΠΔΛΑΗ

20 Why transradial approach for Primary PCI?

21

22 Mortality & Bleeding / Transfusion Doyle et al, JACC 2009; 53:

23 SITES OF BLEEDING OVERALL NSTEMI STEMI JACC Vol. 55, No. 20, 2010 Transradial Approach for PCI May 18, 2010:

24 RIVAL Study: Subgroups: Primary Outcome Death, MI, Stroke or non-cabg major Bleed Overall Age <75 75 Gender Female Male BMI < >35 Radial PCI Volume by Operator >142.5 Radial PCI Volume by Centre Lowest Tertile Middle Tertile Highest Tertile Diagnosis at presentation NSTE-ACS STEMI 0.25 Hazard Ratio (95% CI) Radial better Femoral better p-value Interaction

25 Romagnoli et al. TCT 2011 RIFLE-STEACS study: Reduction in bleeding with TR access 30-day bleeding rate

26 STEMI RADIAL - results 30-day NACE p = % 58% 4.6% p = % 80% 1.4% 4.2% p = % Net Adverse Clinical Event (NACE) = MACE + major bleeding MACE = composite of death, myocardial infarction and stroke I Bernat TCT 2012

27 21 studies 8534 pts EuroIntervention 2012;8:

28 Mortality in the TRA vs TFA EuroIntervention 201 2; 8:

29 Ongoing Randomized Trials Comparing TRA-TFA RADIAL-CABG : 128 pts Diagnostic-PCI STEMI-RADIAL : 700 pts Acute MI SAFARI-STEMI : 1274 pts Acute MI MATRIX : 6800 pts ACS SAFE-PCI for WOMEN : 3000 pts Diagnostic-PCI ClinicalTrials.gov

30 LEARNING CURVE JACC Vol. 55, No. 20, 2010 Transradial Approach for PCI May 18, 2010:

31 LEARNING CURVE Procedural Failure for TRA 10% in the first 50 cases 3-4% after other 500 <1% only after 1000 Louvard Y. Am J Cardiol :

32

33

34 CONCLUSIONS TRA is specially effective in high risk populations like old patients, AMI, patients treated with powerful anticoagulant or antiplatelet drugs. Modern interventional cardiologist should adopt TRA as first choise. The effectiveness of radial procedures might be linked to operator s expertise and a center s volume

35 ΕΥΦΑΡΙΣΤΩ

36 Meta-analysis 1:- Radial vs Femoral Agostoni et al, JACC 2004; 44:

37 Meta-analysis 2: Radial vs Femoral 23 studies included spanning Major Bleeding: Radial: 0.5% (13 / 2390 pts) Femoral: 2.3% (48 / 2068 pts) OR: 0.27 (95% CI , p < 0.001) Trend towards reduced composite of death / MI / stroke OR: 0.71 (95% CI , p = 0.058) Trend towards reduced mortality OR 0.74 (95% CI , p = 0.29) Jolly et al, Am Heart J 2009; 157: )

38 MORTAL Study Access Site Odds Ratios (adjusted for baseline characteristics) for receiving a transfusion based on Radial vs Femoral access: 0.59 (95% CI 0.48 to 0.73), p < Adjusted OR for mortality: TRA v TFA 30 day: 0.71 (95% CI 0.61 to 0.82) p < year: 0.83 (95% CI 0.71 to 0.98) P < If only non-transfused procedures analyzed, difference in mortality non-significant Supports hypothesis that mortality difference closely linked with need for transfusion Chase et al, Heart 2008; 94:

39 RIVAL (RadIal Vs femoral access for PCI) Study Design NSTE-ACS and STEMI (n=7021) Randomization 3831 (45%) pts were sub-study of OASIS-7 Trial Key Inclusion: Intact dual circulation of hand required Interventionalist experienced with both (minimum 50 radial procedures in last year) Radial Access (n=3507) Femoral Access (n=3514) Blinded Adjudication of Outcomes Primary Outcome: Death, MI, stroke or non-cabg-related Major Bleeding at 30 days Jolly S et al. published online Lancet April 4, 2011

40 RIVAL TRIAL Primary and Secondary Outcomes at 30 days Radial (n=3507) Femoral (n=3514) % p= p= Death, MI, Stroke, or non CABG Bleeding Death, MI or Stroke Jolly S published online at thelancet.com April 4, 2011

41 Cumulative analysis of major adverse cardiac events. EuroIntervention 201 2; 8:

42 PCI and Bleeding

43

44 RIVIERA Study: Death / MI Montelescot et al, Int J Card 2008; 129(3):

45 RIVIERA Study: Bleeding Montelescot et al, Int J Card 2008; 129(3):

46

47 RADIAL APPROACH PENETRATION 60% in France 20% in Europe 1.5% in USA Louvard Y Ann Cardiol Angeiol (Paris) 2009;58:327-32

48 Choice of Site and Arterial Access The strongest multivariate predictors of femoral vascular complication during PCIs were: Age > 70 years Female sex Body surface area <1.6 m2 Renal failure or creatinine > 2mg/dl Emergent procedures Larger sheath sizes/iapb use Anticoagulation regimen: IIb/IIIa inhibitors and preprocedural use of thienopyridines Piper WD AHL 2003

49 Meta-analysis of Bleeding in ACS Hamon et al, EuroIntervention 2007; 3:

50 PROCERURAL and CLINICAL OUTCOMES after TRA PCI JACC Vol. 55, No. 20, 2010 Transradial Approach for PCI May 18, 2010:

51 MORTAL Study British Columbia Cardiac Registry used to evaluate patients who had undergone PCI from Cross-referenced with Central Transfusion Registry to identify patients transfused within 10 days of PCI Objective: To determine association of arterial access site (radial vs femoral) with transfusion and mortality Chase et al, Heart 2008; 94:

52 RIVAL Study: Conclusions Overall Trans-radial approach was similar to Trans-femoral approach in terms of MACE with lower vascular complications in the radial group TRI had advantage over TFI in STEMI pts in having lower MACE and even lower mortality, perhaps largely driven by lower vascular/bleeding complications Radial approach had higher access site crossover without compromising PCI procedural success and was associated with higher radiation exposure The effectiveness of radial procedures might be linked to operator s expertise and a center s volume Jolly S et al. published online Lancet April 4, 2011

53 Radial PCI in STEMI - MACE Azmendi et al, Am J Card 2010; 106(2):

54 Major Femoral Bleeding Post-PCI Doyle et al, JACC Interventions 2008 ; 1: 202-9

55 Bleeding rates reduced with Bivalirudin, but are still 5% in STEMI Stone G, et al, NEJM 2008;358 :

56 First Randomized Comparison of Elective PCI via TRA-TBA-TFA

57 First prospective multi-center randomized AMI-TRI trial Catheterization and Cardiovascular Interventions 59:26 33 (2003)

58 Meta-analysis in STEMI Patients MORTALITY MAJOR BLEEDING ACCESS SITE COMPLICATION MACE Mamas A. Heart 2012;98:

Overview of Trasradial Approach for Coronary Angiography and Intervention. A/Prof. Phạm Mạnh Hùng, MD.FACC., FESC

Overview of Trasradial Approach for Coronary Angiography and Intervention. A/Prof. Phạm Mạnh Hùng, MD.FACC., FESC Overview of Trasradial Approach for Coronary Angiography and Intervention A/Prof. Phạm Mạnh Hùng, MD.FACC., FESC Outline Historical perspective and current trends Rationale for the radial approach Bleeding

More information

TRANSRADIAL CARDIAC CATHETERIZATION. Amanda Ryan, DO, Interventional Cardiologist Heart Care Centers of Florida April 13, 2013

TRANSRADIAL CARDIAC CATHETERIZATION. Amanda Ryan, DO, Interventional Cardiologist Heart Care Centers of Florida April 13, 2013 TRANSRADIAL CARDIAC CATHETERIZATION Amanda Ryan, DO, Interventional Cardiologist Heart Care Centers of Florida April 13, 2013 TOPICS Historical perspective and current trends Rationale Bleeding for the

More information

ΚΕΡΚΙΔΙΚΗ ΠΡΟΠΕΛΑΗ ΑΝΑΚΟΠΗΗ ΣΕΛΕΤΣΑΙΩΝ ΔΕΔΟΜΕΝΩΝ

ΚΕΡΚΙΔΙΚΗ ΠΡΟΠΕΛΑΗ ΑΝΑΚΟΠΗΗ ΣΕΛΕΤΣΑΙΩΝ ΔΕΔΟΜΕΝΩΝ ΚΕΡΚΙΔΙΚΗ ΠΡΟΠΕΛΑΗ ΑΝΑΚΟΠΗΗ ΣΕΛΕΤΣΑΙΩΝ ΔΕΔΟΜΕΝΩΝ Dr ΝΙΚΟΛΑΟΣ ΚΑΥΚΑΣ MD, FESC Διεσθσνηής, Υπεύθσνος Αιμοδ/κού Εργαζηηρίοσ Καρδιολογική Κλινική Γεν. Νοζοκομείο Κ.Α.Τ. OUTLINE Introduction Radial in the world

More information

Radial Artery Access Improving Outcomes and Decreasing Costs

Radial Artery Access Improving Outcomes and Decreasing Costs Howard A. Cohen, MD, FACC, FSCAI Director, Division of Cardiac Intervention Co-Director, Cardiac Catheterization Laboratories Lenox Hill Heart & Vascular Institute Institute DISCLOSURE Nothing to disclose

More information

Transradial vs. Transfemoral Access in STEMI: Should We Randomize?

Transradial vs. Transfemoral Access in STEMI: Should We Randomize? Transradial vs. Transfemoral Access in STEMI: Should We Randomize? Ajay J. Kirtane, MD, SM Center for Interventional Vascular Therapy Columbia University Medical Center / New York Presbyterian Hospital

More information

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post

More information

Access Issues and Bleeding Complications

Access Issues and Bleeding Complications Cardiovascular Trends 2011: Nursing and Cath Lab Symposia ITS 2011 Access Issues and Bleeding Complications Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor

More information

Bivalirudin Clinical Trials Update Evidence and Future Perspectives

Bivalirudin Clinical Trials Update Evidence and Future Perspectives Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS

More information

Switching from femoral to radial access for coronary angiography in ACS

Switching from femoral to radial access for coronary angiography in ACS ORIGINAL ARTICLE 169 Feasability, bleeding events and impact on door-to-balloon times Switching from femoral to radial access for coronary angiography in ACS Ivano Reho, Martin Sprenger, David Tueller,

More information

STEMI AND MULTIVESSEL CORONARY DISEASE

STEMI AND MULTIVESSEL CORONARY DISEASE STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related

More information

Is the role of bivalirudin established?

Is the role of bivalirudin established? Is the role of bivalirudin established? Rob Henderson Consultant Cardiologist Trent Cardiac Centre Nottingham University Hospitals Conflicts of Interest: None Declarations: Member NICE Unstable Angina

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN

What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN October 2011 Part 2 Summary of newer antithrombotic and antiplatelet agents in STEMI Role of thrombectomy in PPCI

More information

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical

More information

Updated and Guideline Based Treatment of Patients with STEMI

Updated and Guideline Based Treatment of Patients with STEMI Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv

More information

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle  holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :

More information

CPORT E Trial. Atlantic C PORT

CPORT E Trial. Atlantic C PORT CPORT E Trial Randomized trial comparing medical, economic and quality of life outcomes of non primary PCI at hospitals with and without on site cardiac surgery Mo#va#on for Trial Sustain primary PCI program

More information

Neurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization.

Neurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization. Neurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization Dr Paolo Buja Trend Patients undergoing PCI in UK FEMORAL RADIAL Ratib JACC

More information

PCI Update Qesaria 2009

PCI Update Qesaria 2009 PCI Update Qesaria 2009 Amit Segev Interventional Cardiology Chaim Outline Primary PCI Non-ST elevation ACS Multi-vessel disease Hemodynamic assessment of borderline lesions - FFR Stable AP Non-coronary

More information

Belinda Green, Cardiologist, SDHB, 2016

Belinda Green, Cardiologist, SDHB, 2016 Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens

More information

PERCUTANEOUS CORONARY INTERVENTION AND BLEEDING COMPLICATIONS

PERCUTANEOUS CORONARY INTERVENTION AND BLEEDING COMPLICATIONS PERCUTANEOUS CORONARY INTERVENTION AND BLEEDING COMPLICATIONS *Sudhakar George, 1 Rob Butler, 1,2 James Nolan, 1,2 Mamas A. Mamas 1,2 1. Royal Stoke University Hospital, Stoke-on-Trent, UK 2. Keele Cardiovascular

More information

How to manage ACS patients with Comorbidities? Patients with Renal Failure

How to manage ACS patients with Comorbidities? Patients with Renal Failure How to manage ACS patients with Comorbidities? Patients with Renal Failure François Schiele, MD, PhD Department of Cardiology, University Hospital Jean Minjoz, Besançon, France. Potential conflicts of

More information

Bivalirudin should be indicated for all patients with STEMI. Adnan Kastrati Deutsches Herzzentrum, Munich, Germany

Bivalirudin should be indicated for all patients with STEMI. Adnan Kastrati Deutsches Herzzentrum, Munich, Germany Bivalirudin should be indicated for all patients with STEMI Adnan Kastrati Deutsches Herzzentrum, Munich, Germany 1 Heparin+IIb/IIIa, heparin alone or bivalirudin in STEMI: Do we have the answer? 2 Heparin+IIb/IIIa,

More information

Cath Conference Kintur Sanghvi MD March 15, 2007

Cath Conference Kintur Sanghvi MD March 15, 2007 Cath Conference Kintur Sanghvi MD March 15, 2007 Case 1: 75 yr old female admitted with chest pain and abnormal stress test t Case 2: 70 yr F with typical exertional angina and HTN, dyslipidemia. Trans

More information

Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC

Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical

More information

Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary

Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor

More information

OBJECTIVES. New Twist To Old Disease: Cardiovascular Update /9/2017. Prevention Pre-operative Coronary Artery Disease

OBJECTIVES. New Twist To Old Disease: Cardiovascular Update /9/2017. Prevention Pre-operative Coronary Artery Disease New Twist To Old Disease: Cardiovascular Update 2017 Sridevi R Pitta, M.D.,MBA, F.S.C.A.I., R.P.V.I Medical Director for STEMI, Medical Director for CV Quality Council, Interventional Cardiologist & Endovascular

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and

More information

Clopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany

Clopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In

More information

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to

More information

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in

More information

Transfemoral access (TFA) through the percutaneous

Transfemoral access (TFA) through the percutaneous Transradial Coronary Intervention in STEMI Patients The current status of this approach and future perspectives on its staying power. By Simone Biscaglia, MD, and Marco Valgimigli, MD, PhD, FESC Transfemoral

More information

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,

More information

No conflict of interest to declare

No conflict of interest to declare Switch and Non-Switch in P2Y12 Inhibition: The Real-Life Use of Clopidogrel and Prasugrel in Patients with Acute Myocardial Infarction. Insights from the FAST MI 2010 Registry. F. Schiele (Besançon), E.

More information

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell

More information

Columbia University Medical Center Cardiovascular Research Foundation

Columbia University Medical Center Cardiovascular Research Foundation STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)

More information

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute

More information

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs

More information

ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ

ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Σημαντικές Εξελίξεις στη Θρόμβωση 2014 2015 TRA 2P TIMI 50 και TRACER Substudies ΚΑΛΑΝΤΖΗ ΚΑΛΛΙΡΡΟΗ Καρδιολόγος ιδάκτωρ Ιατρικής Σχολής Πανεπιστημίου

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our

More information

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization

More information

Freedom to Treat Your High Bleeding Risk Patients. Tim Kinnaird University Hospital of Wales, Cardiff, UK

Freedom to Treat Your High Bleeding Risk Patients. Tim Kinnaird University Hospital of Wales, Cardiff, UK Freedom to Treat Your High Bleeding Risk Patients Tim Kinnaird University Hospital of Wales, Cardiff, UK Relevant Disclosures Honoraria for lectures from: o Eli Lilly & Co, Daiichi Sankyo, Boehringer,

More information

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture

More information

Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI

Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI Gamal Abdelhady, Emad Mahmoud Department of interventional

More information

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Learning Objectives. Epidemiology of Acute Coronary Syndrome Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis

More information

Thrombolysis, adjunctive pharmacology and interventions

Thrombolysis, adjunctive pharmacology and interventions ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation ESC Annual Congress Munich, 2012 Thrombolysis, adjunctive pharmacology and interventions

More information

Approach to Multi Vessel disease with STEMI

Approach to Multi Vessel disease with STEMI Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre

More information

Is there a real need for new agents to optimize efficacy/safety balance

Is there a real need for new agents to optimize efficacy/safety balance Anticoagulation in acute coronary syndrome Is there a real need for new agents to optimize efficacy/safety balance Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures

More information

Optimal Duration and Dose of Antiplatelet Therapy after PCI

Optimal Duration and Dose of Antiplatelet Therapy after PCI Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI

More information

Euro-Asia CTO Club Can we Implement Japanese Techniques in Europe?

Euro-Asia CTO Club Can we Implement Japanese Techniques in Europe? Euro-Asia CTO Club Can we Implement Japanese Techniques in Europe? T. Lefèvre,, Massy, France Background Despite continuous improvement, PTCA of chronic total occlusion remains a real technical challenge.

More information

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential

More information

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Which drug do you prefer for stable CAD? - P2Y12 inhibitor Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,

More information

Optimal lenght of DAPT in different clinical scenarios

Optimal lenght of DAPT in different clinical scenarios Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk

More information

Acute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT

Acute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Acute coronary syndromes A European viewpoint Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Potential conflicts of interest In the past 2 years Felicita

More information

Trial Update- TOTAL. Jonathan Byrne

Trial Update- TOTAL. Jonathan Byrne Trial Update- TOTAL Jonathan Byrne No conflicts of interest Background- rationale for thrombectomy Major Limitation of primary PCI: distal embolisation and reduced flow Stonel JACC 2002;39:591-7 Henriques

More information

Upstream P2Y 12 RB. Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia

Upstream P2Y 12 RB. Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia Upstream P2Y 12 RB Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia Dio può essere dimostrato Le dimostrazioni dell esistenza di Dio IA Dio non può essere dimostrato

More information

Clinical Lessons from BMC2-PCI

Clinical Lessons from BMC2-PCI Clinical Lessons from BMC2-PCI The Blue Cross Blue Shield of Michigan Cardiovascular Consortium Hitinder Gurm, M.D. University of Michigan Overview 32 papers since inception 10 papers published this year

More information

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY ACUTE CORONARY SYNDROME PCI IN THE ELDERLY G.KARABELA MD.PhD ATHENS NAVAL HOSPITAL INTERVENTIONAL CARDIOLOGY DEPARTMENT NO CONFLICT OF INTEREST TO DECLAIRE Risk stratification in Αcute Coronary Syndrome.

More information

The Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium

The Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium The Window for Fibrinolysis Frans Van de Werf, MD, PhD Leuven, Belgium ESC STEMI Guidelines : December 2008 Reperfusion Therapy: Fibrinolytic Therapy Recommendations Class LOE In the absence of contraindications

More information

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies Mohammad Zubaid, MB, ChB, FRCPC, FACC Professor of Medicine, Kuwait University Chairman, Faculty of Cardiology,

More information

Angioplastica coronarica nel paziente anziano ad alto rischio emorragico

Angioplastica coronarica nel paziente anziano ad alto rischio emorragico Attualità in Cardiologia Aprilia, Enea Hotel 22 ottobre 2011 Angioplastica coronarica nel paziente anziano ad alto rischio emorragico Fabrizio Tomai, MD, FACC, FESC Dept. of Cardiovascular Sciences - Interventional

More information

Case Challenges in ACS The Very Elderly in the Cath Lab

Case Challenges in ACS The Very Elderly in the Cath Lab Case Challenges in ACS The Very Elderly in the Cath Lab Sameh Salama, MD, FSCAI Professor of Cardiology, Cairo University 86 yrs old male IDDM (controlled on insulin and oral hypoglycemics) Hypertensive

More information

RIVAL study: RadIal Vs. femoral access for coronary intervention in patients with acute coronary syndromes study. Sanjit Jolly MD, MSc FRCPC

RIVAL study: RadIal Vs. femoral access for coronary intervention in patients with acute coronary syndromes study. Sanjit Jolly MD, MSc FRCPC RIVAL study: RadIal Vs. femoral access for coronary intervention in patients with acute coronary syndromes study Sanjit Jolly MD, MSc FRCPC Rationale Prior small trials and meta-analyses have demonstrated

More information

On admission Acute extensive anterior STEMI

On admission Acute extensive anterior STEMI Mr B 52 years old male Smoker No prior known CAD Presents with 1 hour intermittent crushing retrosternal chest pain Transferred by MICU directly to CCU (ASA, Heparin) On admission Intense pain, diaphoretic

More information

Άγγελος Παπανικολάου MD, Ειδικευόμενος Καρδιολογίας, A Πανεπιστημιακή Καρδιολογική Κλινική, ΓΝΑ Ιπποκράτειο

Άγγελος Παπανικολάου MD, Ειδικευόμενος Καρδιολογίας, A Πανεπιστημιακή Καρδιολογική Κλινική, ΓΝΑ Ιπποκράτειο Άγγελος Παπανικολάου MD, Ειδικευόμενος Καρδιολογίας, A Πανεπιστημιακή Καρδιολογική Κλινική, ΓΝΑ Ιπποκράτειο Endovascular access & closure Seldinger SI. Catheter replacement of the needle in percutaneous

More information

Supplementary Table S1: Proportion of missing values presents in the original dataset

Supplementary Table S1: Proportion of missing values presents in the original dataset Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)

More information

TRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital

TRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation

More information

Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)

Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Dimitrios Alexopoulos, MD, FESC, FACC Cardiology Department, Patras University Hospital, Patras, Rio, Greece. Patras University Hospital I, Dimitrios

More information

Transition from TF to TR Access in IO: Effect on Patient Radiation Exposure and Fluoroscopy Time

Transition from TF to TR Access in IO: Effect on Patient Radiation Exposure and Fluoroscopy Time Transition from TF to TR Access in IO: Effect on Patient Radiation Exposure and Fluoroscopy Time Mircea Cristescu, Amanda Smolock, George Carberry, Prasad Dalvie, John Fallucca, Paul Laeseke, Orhan Ozkan,

More information

Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute

Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute Implications of Pre-loading on Patients Undergoing Coronary Angiography Angiography Define

More information

Reperfusion Strategy in Europe: Temporal Trends in Performance Measures for Reperfusion Therapy in ST Elevation Myocardial Infarction

Reperfusion Strategy in Europe: Temporal Trends in Performance Measures for Reperfusion Therapy in ST Elevation Myocardial Infarction Reperfusion Strategy in Europe: Temporal Trends in Performance Measures for Reperfusion Therapy in ST Elevation Myocardial Infarction F. Schiele 1, M. Hochadel 2, M. Tubaro 3, N. Meneveau 1, W. Wojakowski

More information

Timing of Surgery After Percutaneous Coronary Intervention

Timing of Surgery After Percutaneous Coronary Intervention Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet

More information

Optimal Duration of Dual Anti- Platelet Therapy. December 19, 2015

Optimal Duration of Dual Anti- Platelet Therapy. December 19, 2015 Optimal Duration of Dual Anti- Platelet Therapy December 19, 2015 John S. MacGregor, M.D., Ph.D. Professor of Medicine University of California San Francisco Source: The New Yorker 1 Optimal Duration of

More information

Pharmaco-Invasive Approach for STEMI

Pharmaco-Invasive Approach for STEMI Pharmaco-Invasive Approach for STEMI Michael C. Kontos, MD Medical Director, Coronary Intensive Care Unit Director, Chest Pain Evaluation Center Associate Professor Departments of Internal Medicine (Cardiology),

More information

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden

More information

Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction

Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4

More information

Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI

Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart

More information

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et

More information

Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές

Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές 4 ο ΠΑΝΕΛΛΗΝΙΟ ΑΡΡΥΘΜΙΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ 21-22 ΣΕΠΤΕΜΒΡΙΟΥ 2018 HILTON, ΑΘΗΝΑ Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές Ι. Κανακάκης MD, PhD Διευθυντής Αιμοδυναμικού Τμήματος

More information

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck. DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets

More information

Ischemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland

Ischemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland Ischemic and bleeding risk stratification in NSTE ACS Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland Disclosure Andrzej Budaj, MD, PhD, reports the following potential conflicts

More information

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet

More information

Adjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013

Adjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013 Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville

More information

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators

More information

Optimal antithrombotic therapy:

Optimal antithrombotic therapy: Optimal antithrombotic therapy: upstream and during primary PCI. Steen D Kristensen, MD, DMSc, FESC Professor and Consultant Interventional Cardiologist Aarhus University, Denmark UNIVERSITY OF AARHUS

More information

Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)

Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Multivessel disease and cardiogenic shock: CABG is the optimal revascularization therapy. Contra Prof. Christian JM Vrints Cardiogenic Shock Spiral Acute Myocardial

More information

Is Cangrelor hype or hope in STEMI primary PCI?

Is Cangrelor hype or hope in STEMI primary PCI? Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect

More information

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,

More information

SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION?

SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION? SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION? Doron Zahger, MD Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion

More information

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual

More information

Ischemic Heart Disease: The 5 Most Important Trials in the Last Year

Ischemic Heart Disease: The 5 Most Important Trials in the Last Year Torino, IT October 2015 Ischemic Heart Disease: The 5 Most Important Trials in the Last Year Malcolm R. Bell, MBBS, FRACP Director Ischemic Heart Disease Program Mayo Clinic, MN, USA 2013 MFMER slide-1

More information

ST-Elevation MI: Update on Bivalirudin and DES

ST-Elevation MI: Update on Bivalirudin and DES ST-Elevation MI: Update on Bivalirudin and DES George D. Dangas, MD, FACC, FSCAI, FAHA Professor of Medicine Director, Cardiovascular Innovation Mount Sinai Medical Center, New York, NY Disclosure Research

More information

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, G. PAPANIKOLAOU GH, THESSALONIKI The Impact of AF on Natural History of CAD DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI CAD MOST COMMON CARDIOVASCULAR DISEASE MOST COMMON CAUSE OF DEATH

More information

Do We Need Platelet Function Assays?

Do We Need Platelet Function Assays? Do We Need Platelet Function Assays? Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA The Antiplatelet Effect of Clopidogrel Varies Widely Among Individuals

More information

Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI

Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Ομάδες Εργασίας Φεβρουάριος 2016 Ξανθοπούλου Ιωάννα Καρδιολόγος Επιμ Β ΠΓΝΠατρών Nothing to disclose Platelet function testing (PFT) is helpful in identifying

More information

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current

More information

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants

More information